Reagent update
Current availability from MHRA of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2024-25 Northern hemisphere season and 2025 Southern hemisphere season (see below for pricing information)
More information can be found in the Influenza Resource Centre pages
Update 20 December 2024
Candidate influenza viruses for use in the Southern hemisphere 20251
Candidate influenza vaccine viruses
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/4897/2022
|
23/252
|
|
IVR-238 reassortant derived from A/Victoria/4897/2022
|
23/250
|
|
A/West Virginia/30/2022
|
23/122
|
|
A/Wisconsin/67/2022
|
23/120
|
|
A/Norway/31694/2022
|
22/312
|
|
NIB-133 reassortant derived from A/Norway/31694/2022
|
23/112
|
|
NIB-134 reassortant derived from A/Catalonia/NSVH161512065/2022
|
23/126
|
|
CNIC-2301 reassortant derived from A/Sichuan-Qingyang/SWL1148/2023
|
23/214
|
|
H3N2
|
|
|
A/Croatia/10136RV/2023
|
24/160
|
|
NIB-146 reassortant derived from A/Croatia/10136RV/2023
|
24/158
|
|
NYMCX-425A reassortant derived from A/Croatia/10136RV/2023
|
24/162
|
|
A/District of Columbia/27/2023
|
24/166
|
|
NIB-142 reassortant derived from A/District of Columbia/27/2023
|
24/164
|
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021
|
23/228
|
|
BVR-26 reassortant derived from B/Austria/1359417/2021
|
22/204
|
|
BX-107A reassortant derived from B/Austria/1359417/2021
|
22/134
|
|
B/Michigan/01/2021
|
21/244
|
|
B/Singapore/WUH4618/2021
|
21/242
|
|
B/Guangdong-Zhenjiang/1516/2021
|
21/388
|
1Recommendations announced for influenza vaccine composition for the 2025 southern hemisphere influenza season (who.int)
Access To B/Yamagata lineage viruses is currently restricted.
Please contact Othmar.Engelhardt@mhra.gov.uk and Jason.Long@mhra.gov.uk
SRD reagents for use in the Southern hemisphere 20251
Reagents for influenza vaccine standardisation
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/4897/2022 (IVR-238) antigen
|
22/320
|
|
A/Georgia/12/2022 (CVR-167) (cell derived) antigen
|
24/198 (under calibration)
|
|
A/Victoria/4897/2022 - like antiserum
|
23/100
|
|
H3N2
|
|
|
A/Croatia/10136RV/2023 (NYMC X-425A)) antigen
|
24/174
|
|
A/Croatia/10136RV/2023– like antiserum
|
24/176
|
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021 (BVR-26) antigen
|
21/316
|
|
B/Michigan/01/2021 antigen
|
21/330
|
|
B/Singapore/WUH4618/2021 (cell derived) antigen
|
23/268
|
|
B/Austria/1359417/2021 - like antiserum
|
22/228
|
|
B (Yamagata lineage)
|
|
|
B/Phuket/3073/2013 antigen
|
21/136
|
|
B/Utah/9/2014 (cell derived) antigen
|
15/100
|
|
B/Singapore/INFTT-16-0610/2016 (cell derived) antigen
|
19/308
|
|
B/Phuket/3073/2013 - like antiserum
|
22/132
|
1Recommendations announced for influenza vaccine composition for the 2025 southern hemisphere influenza season (who.int)
Neuraminidase reagents in use
Neuraminidase reagents
|
NIBSC code
|
|
N1
|
|
|
NA antiserum prepared from A/California/7/2009
|
10/218
|
|
NA antiserum prepared from A/New Caledonia/20/99
|
04/230
|
|
NA antiserum prepared from A/Victoria/4897/2022
|
23/208
|
|
N2
|
|
|
NA antiserum prepared from A/Victoria/361/2011
|
14/144
|
|
NA antiserum prepared from A/South Australia/34/2019
|
19/320
|
|
B
|
|
|
NA antiserum prepared from B/Jiangsu/10/2003
|
04/228
|
|
NA antiserum prepared from B/Malaysia/2506/2004
|
05/252
|
|
NA antiserum prepared for B/Florida/4/2006
|
09/316 please contact for availability
|
|
NA antiserum prepared from B/Phuket/3073/2013
|
21/322
|
Candidate influenza viruses for use in the Northern hemisphere 2024-20252
Candidate influenza vaccine viruses
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/4897/2022
|
23/252
|
|
IVR-238 reassortant derived from A/Victoria/4897/2022
|
23/250
|
|
A/West Virginia/30/2022
|
23/122
|
|
A/Wisconsin/67/2022
|
23/120
|
|
A/Norway/31694/2022
|
22/312
|
|
NIB-133 reassortant derived from A/Norway/31694/2022
|
23/112
|
|
NIB-134 reassortant derived from A/Catalonia/NSVH161512065/2022
|
23/126
|
|
H3N2
|
|
|
A/Thailand/8/2022
|
24/154
|
|
IVR-237 reassortant derived from A/Thailand/8/2022
|
23/206
|
|
A/California/122/2022
|
23/200
|
|
SAN-022 reassortant derived from A/California/122/2022
|
23/234
|
|
A/Brisbane/837/2022
|
23/216
|
|
IVR-246 reassortant derived from A/Brisbane/837/2022
|
23/238
|
|
A/Brandenburg/15/2022
|
23/202
|
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021
|
23/228
|
|
BVR-26 reassortant derived from B/Austria/1359417/2021
|
22/204
|
|
B/Michigan/01/2021
|
21/244
|
|
B/Singapore/WUH4618/2021
|
21/242
|
|
B/Guangdong-Zhenjiang/1516/2021
|
21/388
|
2Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season (who.int)
SRD reagents for use in the Northern hemisphere 2024-252
(For H1N1 subtype, B Victoria and Yamagata lineage reagents please see tables for Southern hemisphere 2025 above)
Reagents for influenza vaccine standardisation
|
NIBSC code
|
|
H3N2
|
|
|
A/Thailand/8/2022 (IVR-237) antigen
|
23/220
|
|
A/California/122/2022(SAN-022) antigen
|
23/226
|
|
A/Thailand/8/2022 – like antiserum
|
23/222
|
2Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season (who.int)
Pricing information
Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to a handling fee as stated on the product information page, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the handling fee.
Calibration of Reagents for Influenza vaccine standardisation
Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:
Essential Regulatory Laboratories (ERL)
- Medicines and Healthcare products Regulatory Agency (MHRA), UK
- Center for Biologics Evaluation and Research (CBER), USA
- National Institute for Infectious Disease (NIID), Japan
- Therapeutic Goods Administration (TGA), Australia